Skip to content
Open access

Intelligent Automation Improved Efficiency in Pharmacovigilance Safety Signal Assessment

Jul 2026 · Clinical pharmacology and therapy · 0 citations · 19 references
Medicine

TL;DR

These results are the first to demonstrate an intelligent automation platform that may streamline signal management workflows using a machine‐first, human‐verified operational workflow while maintaining regulatory compliance.

Abstract

Pharmacovigilance is the science involving the detection, assessment, understanding, and prevention of adverse events associated with drugs, biologics, or medical devices. In pharmacovigilance, information that suggests a new potential causal relationship between an intervention and an adverse event is called a safety signal. Following their detection, safety signals are assessed via a comprehensive, structured analysis to more fully elucidate whether a correlation exists. This key process often requires the manual assessment of many individual case safety report (ICSR) narratives to extract meaningful information in a labor‐intensive, time‐consuming, and variability‐prone manner. In this retrospective feasibility study, we describe the potential utility of an intelligent automation system leveraging the GPT‐4o large language model to automate the extraction of case elements of interest from a series of ICSR narratives while maintaining human expert oversight. Our proprietary platform allowed users to extract the presence or absence of risk factors and responses to dechallenge and rechallenge via instructional prompts built on a common template structure. Case elements for five historical signal assessments were selected based on need for and feasibility of artificial intelligence extraction. Performance ranged from F1 = 0.444 to 1.000 for risk factors and from F1 = 0.429 to 0.909 for responses to dechallenge and rechallenge. Even when considering the need to verify GPT‐4o outputs for accuracy, potential time savings were identified. To the best of our knowledge, our results are the first to demonstrate an intelligent automation platform that may streamline signal management workflows using a machine‐first, human‐verified operational workflow while maintaining regulatory compliance.

Read PDF

Similar papers

Open access Aug 2026

Signal mining and safety profile analysis of prucalopride: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database

Prucalopride is a highly selective 5-HT 4 agonist used for chronic idiopathic constipation and gastroparesis. Although clinical trials suggest a favorable safety profile, real-world data on rare adverse events (AEs) remain scarce. This study mined the FDA Adverse Event Reporting System (FAERS) to detect safet...

Zhongjing Meng, Wen-Jie Li, Jingjing Lu et al. · 0 citations
Review Open access Aug 2026

Optimising Pharmacovigilance Efficiency with MLIT (Machine Learning for Intelligent Triage): A Tool for Statistical Safety Alerts.

This study highlights the potential of ML-based tools to improve pharmacovigilance by enhancing signal detection performance, reducing the likelihood of missed signals, while increasing operational efficiency, and strengthening reproducibility and transparency.

Luciano Ciccarelli, Olivia Mahaux, Christie Roshan et al. · 0 citations
Open access Jul 2026

Possibility of using artificial intelligence models in routine pharmacovigilance processes

A critical analysis of the potential of NLP systems to optimize routine PV tasks, taking into account data protection requirements is provided, and AI can become a robust tool for increasing the efficiency of PV processes.

Y. Shirobokov, Yu. A. Molchanova, E. P. Chumak et al. · 0 citations
Review Jul 2026

Using Artificial Intelligence to Identify Patterns and Predictors of Adverse Drug Reactions in Cardiovascular Patients: A Comprehensive Narrative Review

This narrative review synthesizes current evidence on AI applications across the cardiovascular PV continuum, including safety signal detection, patient-level risk prediction, and text-based surveillance and holds substantial promise for enhancing cardiovascular drug safety.

Erfan Shahabinejad, Fatemeh Soflaei-Shahrbabak, Marzieh Gholami Shoa et al. · 0 citations
Conference Jul 2026

Adverse Drug Event Prediction in Pharmacovigilance Using KG-Augmented LLM

Adverse drug events (ADEs), referring to harmful and unintended reactions from routine medication use, continue to pose a significant challenge for pharmacovigilance, one that can be addressed through AI-enabled Web services. In the United States, more than two million serious ADEs have been reported among hospitalized...

Shirish Bajpai, V. S. S. Anirudh Sharma, Aman Tomar et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.